Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABOSTO:BOUL -6.67%48 ROC (Joel Greenblatt) % is 1.34% as of Jun. 2026, which is 94% below its 10-year median of 23.02. GuruFocus rates OSTO:BOUL with a GF Score™ of 48/100 and a GF Value™ of kr6.52 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 838 Medical Devices & Instruments companies, Boule Diagnostics AB ranks better than 61.46% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Boule Diagnostics AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 1.34%.
The historical rank and industry rank for Boule Diagnostics AB's ROC (Joel Greenblatt) % or its related term are showing as below:
OSTO:BOUL'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -216.77 Med: 23.02 Max: 55.13
Current: 11.57
During the past 13 years, Boule Diagnostics AB's highest ROC (Joel Greenblatt) % was 55.13%. The lowest was -216.77%. And the median was 23.02%.
OSTO:BOUL's ROC (Joel Greenblatt) % is ranked better than 61.46% of 838
companies
in the Medical Devices & Instruments industry
Industry Median: 4.145
vs OSTO:BOUL: 11.57
Boule Diagnostics AB's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Boule Diagnostics AB (OSTO:BOUL) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Boule Diagnostics AB ROC (Joel Greenblatt) % Related Terms
Boule Diagnostics AB ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB ROC (Joel Greenblatt) % Chart
OSTO:BOUL vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's ROC (Joel Greenblatt) % falls into.
Boule Diagnostics AB ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 1.34% mean?
Boule Diagnostics AB (OSTO:BOUL) has a ROC (Joel Greenblatt) % of 1.34% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Boule Diagnostics AB and its competitors. This is 94% below median its historical median of 23.02. According to the industry distribution chart, Boule Diagnostics AB ranks #323 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 38.5%.
Is Boule Diagnostics AB's ROC (Joel Greenblatt) % too high?
Boule Diagnostics AB's current ROC (Joel Greenblatt) % of 1.34% is 94% below median its 10-year median of 23.02. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.15. Boule Diagnostics AB's value of 1.34% is 67.7% below this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #323 out of 838 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Boule Diagnostics AB has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #323 out of 838 companies for ROC (Joel Greenblatt) %. This puts Boule Diagnostics AB in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 4.15. Boule Diagnostics AB's value of 1.34% is 67.7% below this benchmark. While the company's 10-year median is 23.02 vs. the industry median of 4.15, Boule Diagnostics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.15, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current ROC (Joel Greenblatt) % of 1.34% is 67.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current ROC (Joel Greenblatt) % is 1.34%, which is 94% below median its own 10-year median of 23.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Based on GuruFocus' analysis, Boule Diagnostics AB (OSTO:BOUL) is currently considered Possible Value Trap. The stock's GF Value™ is kr6.52, compared to a current price of kr3.36 — trading 48.5% below its estimated fair value. The current ROC (Joel Greenblatt) % is 1.34%, which is 94% below median its 10-year median of 23.02 and 67.7% below the Medical Devices & Instruments industry median of 4.15. Boule Diagnostics AB's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Boule Diagnostics AB (OSTO:BOUL), the current ROC (Joel Greenblatt) % is 1.34% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (OSTO:BOUL) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr3.36 is trading 48.5% below its estimated GF Value™ of kr6.52.
GuruFocus considers Boule Diagnostics AB to be Possible Value Trap.
Key valuation signals for OSTO:BOUL:
ROC (Joel Greenblatt) %: 1.34% (94% below median its 10-year median of 23.02)
GF Value™: kr6.52 vs. price of kr3.36 (48.5% below fair value)
Industry Position: 67.7% below the Medical Devices & Instruments median (#323 of 838)
No single metric tells the full story. See the OSTO:BOUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
48GF Score
Get the complete analysis for OSTO:BOUL
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:BOUL has been successfully added to your 
